These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 28973887

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF.
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [Abstract] [Full Text] [Related]

  • 5. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
    Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK.
    Cancer Res; 2013 May 15; 73(10):3145-54. PubMed ID: 23644530
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase.
    Adelsman MA, McCarthy JB, Shimizu Y.
    Mol Biol Cell; 1999 Sep 15; 10(9):2861-78. PubMed ID: 10473632
    [Abstract] [Full Text] [Related]

  • 18. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK, Piao Y, de Groot JF.
    Clin Cancer Res; 2009 Jul 15; 15(14):4589-99. PubMed ID: 19567589
    [Abstract] [Full Text] [Related]

  • 19. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
    Michaelsen SR, Staberg M, Pedersen H, Jensen KE, Majewski W, Broholm H, Nedergaard MK, Meulengracht C, Urup T, Villingshøj M, Lukacova S, Skjøth-Rasmussen J, Brennum J, Kjær A, Lassen U, Stockhausen MT, Poulsen HS, Hamerlik P.
    Neuro Oncol; 2018 Oct 09; 20(11):1462-1474. PubMed ID: 29939339
    [Abstract] [Full Text] [Related]

  • 20. Beta1 integrin blockade overcomes doxorubicin resistance in human T-cell acute lymphoblastic leukemia.
    Berrazouane S, Boisvert M, Salti S, Mourad W, Al-Daccak R, Barabé F, Aoudjit F.
    Cell Death Dis; 2019 May 01; 10(5):357. PubMed ID: 31043590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.